Precision Diabetes
An emerging leader in enabling precision medicine for diabetes through the use of novel diabetes biomarkers and algorithms
Coronavirus and Diabetes
The dangerous interaction between COVID-19 and type 2 diabetes
Type 2 diabetes is associated with an increased risk of serious complications or death if you get CORONAVIRUS. Observational data indicate that patients with diabetes are at greater risk of SARS-CoV-2 infection, serious illness and death from COVID-19 than patients without diabetes. Preventing type 2 diabetes and controlling hyperglycemia helps to avoid the fatal consequences of coronavirus. The death rate in patients with COVID-19 who have hyperglycemia is 7 times higher. It is possible to act against the dramatic consequences of the interaction between these two pandemics: COVID-19 and type 2 diabetes.
http://www.patiadiabetes.com/en/covid-19-diabetes-the-dangerous-interaction-of-two-pandemics/
PRECision diabetes news
Predicting COVID19 Patient Mortality: 1,5-anhydroglucitol Test More Accurate than HbA1c + Glucose
"This week, Precision Diabetes, Inc. presented data demonstrating that the 1,5-anhydroglucitol blood test (GlycoMark®) is more accurate than commonly used diabetes tests in predicting mortality in hospitalized COVID-19 patients with and without diabetes." (November 2021, Endocrine News)
New Late-Breaking Data at The ADA Show GlycoMark® May Be an Effective Test for COVID-19 Severity
Precision Diabetes, Inc. Presents Data on Precision IGT Prediabetes Test at 2021 Conference
Patia and Precision Diabetes, Inc. Announce New Strategic Collaboration
New Study Suggests GlycoMark May Identify Highest Risk Patients with Diabetes
Contact Us
Precision Diabetes, Inc.
2474 Walnut Street Box 168
Cary, NC 27518 USA
NY Office
500 7th Avenue 8th Floor New York, NY 10018 USA
Office Hours
Monday - Friday: 9:00am - 5:00pm ET
Saturday - Sunday: Close
